

MARTIN THEODORE E

Form 4

November 25, 2008

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MARTIN THEODORE E

2. Issuer Name **and** Ticker or Trading  
Symbol  
APPLIED BIOSYSTEMS INC.  
[ABI]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
APPLIED BIOSYSTEMS INC., 301  
MERRITT 7

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/21/2008

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

(Street)  
NORWALK, CT 06851-1070

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Applied Biosystems Group Common Stock Units	11/21/2008		D		30,345.4 (1)	D	(2) 0

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

Edgar Filing: MARTIN THEODORE E - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 21.3619 (3)	11/21/2008		D	6,000 (3)	(4) 03/22/2009	Applied Biosystems Group Common Stock 6,000 (3)
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 35.7344 (3)	11/21/2008		D	6,000 (3)	(4) 10/21/2009	Applied Biosystems Group Common Stock 6,000 (3)
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 108.3125 (3)	11/21/2008		D	6,000 (3)	(4) 10/19/2010	Applied Biosystems Group Common Stock 6,000 (3)
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 27.975 (3)	11/21/2008		D	8,000 (3)	(4) 10/18/2011	Applied Biosystems Group Common Stock 8,000 (3)
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 20 (3)	11/21/2008		D	8,000 (3)	(4) 10/17/2012	Applied Biosystems Group Common Stock 8,000 (3)
Applied Biosystems Group	\$ 23.215 (3)	11/21/2008		D	7,500 (3)	(4) 10/16/2013	Applied Biosystems Group 7,500 (3)

Director Stock Options-Right to Buy								Common Stock	
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 18.905 (3)	11/21/2008	D	9,200 (3)	(4)	10/21/2014	Applied Biosystems Group Common Stock	9,200 (3)	
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 35.985 (3)	11/21/2008	D	9,000 (3)	(4)	10/18/2017	Applied Biosystems Group Common Stock	9,000 (3)	
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 23.25 (3)	11/21/2008	D	9,000 (3)	(4)	10/21/2015	Applied Biosystems Group Common Stock	9,000 (3)	
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 33.74 (3)	11/21/2008	D	9,000 (3)	(4)	10/20/2016	Applied Biosystems Group Common Stock	9,000 (3)	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MARTIN THEODORE E APPLIED BIOSYSTEMS INC. 301 MERRITT 7 NORWALK, CT 06851-1070	X			

## Signatures

/s/ Thomas P. Livingston, Attorney-in-Fact for Theodore E. Martin 11/25/2008

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: MARTIN THEODORE E - Form 4

Includes 37.91 Applied Biosystems Group Common Stock Units acquired in October 2008 pursuant to the dividend reinvestment feature of the Company's director stock purchase and stock incentive plans.

- (2) On November 21, 2008, the issuer was acquired by Invitrogen Corporation (renamed Life Technologies Corporation) pursuant to an Agreement and Plan of Merger dated as of June 11, 2008 (as amended, the "merger agreement"). All deferred units for shares of the issuer's Applied Biosystems Group common stock ("ABI stock") held by the reporting person at the time of the merger were converted into a right to receive merger consideration pursuant to the merger agreement. The merger consideration for the converted deferred units consists of 0.8261 shares of Life Technologies common stock (plus an additional cash payment of \$1.91 per share paid as a merger consideration adjustment due to the trading price of ABI stock during a period of time specified prior to the merger).

- (3) Pursuant to the merger agreement, upon completion of the merger each outstanding award of options to purchase shares of ABI stock was converted into an award to purchase shares of Life Technologies Corporation common stock. Each new stock option award became an award to purchase shares of Life Technologies common stock in an amount equal to the product of (x) 0.8698, multiplied by (y) the number of shares of ABI stock underlying the stock option award outstanding as of closing (rounded down to the nearest share). The exercise price per share of each converted option is equal to the exercise price per share of the option prior to conversion divided by the exchange ratio of 0.8698 (rounded up to the nearest cent).

- (4) All of these ABI stock options were fully vested and free from all restrictions upon the completion of the merger described in Note 2 above. Some of the options held by the reporting person and reported in Table II vested at various dates prior to the merger. Pursuant to the merger agreement, options that had not vested prior to the merger became fully vested upon completion of the merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.